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Summary
The method of autologous platelet labelling with In-111 oxinate, and labelled platelets lifes-
pan, production and sequestration site determination at the Center of Nuclear Medicine, Clinical 
Center of Serbia is the result of 24 years of personal experience in Belgrade and modification and 
improvement of the original method.
The improved method is described, and the significance of platelet lifespan, sequestration 
site and production investigation in 555 patients aged from 3,1-83 years, with clinical diagnosis of 
primary immune thrombocytopenia (ITP), as well as in 6 control healthy subjects is demonstrated.
On the basis of the obtained results, it was possible to confirm diagnosis of ITP in 477 (392 
adults and 85 children) out of 555 patients (86 %) with clinical diagnosis of ITP. In 71 patient (69 
adults and 2 children) out of 555 (13 %) ineffective platelet production was discovered as the me-
chanism of thrombocytopenia (patients had normal platelet lifespan, and ITP was excluded), and 
there were 7 patients (1%) with pseudothrombocytopenia (they had also normal platelet lifespan).
Seventy eight ITP patients were splenectomized after labelled platelets investigation. In all 
patients (100 %) with spleen or predominantly spleen as platelet sequestration site, splenectomy 
results were good. In patients with mixed platelet sequestration (in the spleen and liver), sple-
nectomy results were good in 71 %. In ITP patients with hepatic platelet sequestration good 
splenectomy result was registered in only 20 %, while splenectomy failed in 80 % of patients. 
On the basis of labelled platelets sequestration site determination, it was possible to predict the 
efficacy of splenectomy in ITP patients.
This investigation enabled visualization of 18 accessory spleens in 13 ITP patients (in 2,7 % 
of ITP patients) and their role in thrombocytopenia could be estimated.
Unstable atherosclerotic plaques and acute thrombosis were visualized in ITP patients. Chro-
nic thrombosis could not be registered because of the finished thrombus formation and no more 
platelet deposition.
Keywords: 111In-oxinate labelled platelets, immune thrombocytopenia, splenectomy result 
prediction
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INTRODUCTION
The history of platelet labelling goes back to 1956 when Leeksma and Cohen 
used radionuclide phosphorus-32 incorporated into diisopropylfluorophosphonate 
(32P-DFP) for that purpose [1]. Only platelet (Pt) lifespan (without Pt production and 
sequestration site) could be determined, due to the physical characteristics of 32P. 
Aas and Gardner in 1958 [2], and Najean in 1959 [3] introduced chromium-51 in the 
form od sodium-chromate (51Cr-Na2CrO4) for platelet labelling. Both Pt lifespan and 
sequestration site could be estimated, but no images were available due to the low 
gamma photon yield and non-optimal gamma photon energy of 51Cr for detection 
with nuclear medicine equipment. Contemporary method of Pt labelling is related 
to Thakur [4] and indium-111 (111In), which offered good quality images. In Serbia 
111In-oxinate was introduced for the purpose of Pt labelling, Pt lifespan, Pt producti-
on and Pt sequestration site determination in 1991, at Center of Nuclear Medicine in 
Belgrade, and first results were published in 1993 [5-12]. 
Improved platelet separation and labelling procedure
In order to be labelled, platelets have to be separated from the 60 ml of the who-
le blood sample, by means of differential centrifugation: two slow (at 150 g during 
14 minutes first and 12 minutes second, with 1 minute acceleration and 2 minutes 
slowing down, enabling Pt rich plasma layer to be collected) and one fast centrifuga-
tion (of the Pt rich plasma at 640 g during 14 minutes, with additional 1 minute acce-
leration and 2 minutes slowing down). 111In-oxinate is added to the re-suspended 
platelet pellet (together with the Tampon Tris buffer) and incubation lasting 20 mi-
nutes follows. The washing procedure, using the acidified (up to PH 6,0-6,5) platelet 
poor plasma and centrifugation (at 640 g during 14 minutes) eliminate the unbound 
radioactivity. About 5 ml of spared Pt poor plasma (not used for washing procedu-
re) is added to the re-suspended labelled Pt pellet. Quality control of Pt separation 
and labelling procedure follows: 1) general yield of labelling, GYL, indicating the 
percentage of bound, compared to the used radioactivity (in the control group mean 
value was 84 %, and in ITP group 69,1 %; the difference was due to lower Pt blood 
count in ITP group: 1-191 x 109/l, mean value 45 x 109/l, compared to 214-266 x 109/l, 
mean value 255 x 109/l in the control group); 2) differential yield of labelling, DYL, 
showing the percentage of radioactivity bound to: platelets themselves, RBC+WBC, 
plasma, compared to the total bound radioactivity (mean Pt DYL in controls was 
98,3 % and in ITP patients 94,7 %; mean RBC+WBC DYL in ITP was 4,0 and mean 
plasma DYL in ITP was 1,3 %). In addition to laboratory quality control (GYL and 
DYl), in vivo quality control was performed, by acquiring initial dynamic study 
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lasting 20 minutes after 111In-oxinate labelled Pt intravenous injection (40 images, 30 
seconds each), which is the most sensitive parameter for slight platelet damage (le-
ading to temporary initial labelled platelets augmented accumulation in the liver).
Investigation and results of platelet lifespan in 561 subjects
Platelet lifespan (Pt LS) was determined on the basis of the blood samples (3 ml 
each taken at 20 min., 2 h, 4 h after labelled platelets intravenous injection, and once 
a day till the day when blood radioactivity falls to about 10 % of the injected value) 
measurement in the gamma counter. Percentage of the circulating radioactivity (CR) 
was calculated for each moment of blood sample taking, using formula: CR=[(BR/3) / 
IR] x BV x 100 (BR, 3 ml blood sample radioactivity, IR, injected radioactivity, BV, blood 
volume of the investigated person expressed in ml), and the platelet survival curve 
was obtained. In the case of normal Pt lifespan, linear curve was obtained (fig. 1a) and 
platelet lifespan was read at the intercept of the time axis and the extrapolated platelet 
survival curve. In the case of shortened Pt lifespan, exponential curve was obtained 
(fig. 1b), and labelled Pt half disappearance time (T/2) expressed in days was determi-
ned, and Pt LS obtained using the formula: LS=(T/2) / ln2= 1,44 x (T/2). 
Platelet LS in controls ranged 8-10 days (normal values: 7-10 days), mean value 
was 9 days, while in ITP patients it ranged from 0,7-228 hours (mean value was 1,6 
days). Normal Pt LS excluded pathologic Pt destruction. Shortened Pt LS documen-
ted the presence and the degree of pathologic Pt destruction.
1a. Linear platelet survival curve.                          1b. Exponential platelet survival curve.
Figure 1. Platelet survival curves
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Determination and results of platelet production 
Platelet production index (PtPI) was calculated indirectly, using Pt LS and platelet 
blood count (BC) values of the investigated person (I) and healthy subject (H) in the case 
of the linear Pt survival curve: PtPIlin= (HlS x IBC) / (IlS x HBC), where healthy subject Pt LS 
value is 8,5 days and Pt BC value is 300 x 109/l. For the exponential Pt survival curve, Pt 
production index (PtPIexp) was calculated using Pt renewal (R) and BC values of healthy 
(H) and investigated (I) subject: PtPIexp= (IR x IBC) / (HR x HBC). Platelet renewal was cal-
culated according to the formula: R=69,3 / (T/2), where T/2 stands for labelled platelets 
half time (time in days when blood radioactivity falls to 50 % of the injected value). In 
the case when maximal circulating radioactivity (CR) was lower than 50 %, a correction 
factor (F) of PtPIexp was applied and multiplied with the value of PtPI. F=50/CRmax, where 
CRmax is the maximal circulating radioactivity (expressed in percents). 
Platelet production index in controls ranged from 0,8 to 1,2 (mean value was 1,0) 
and in ITP patients from 0,1 to 28 (mean value was 1,4). Therefore, it was possible 
to distinguish two subgroups in our 477 ITP patients: with PtPI lower than 0,5 (48 
patients, 10,1 %) and higher than 0,5 (429 patients, 89,9 %). In subgroup with lower 
PtPI, platelet lifespan was somewhat longer (3,4 days compared to 1,3 days) and Pt 
sequestration index lower (1,1 versus 1,6).
Platelet sequestration site determination and results
Platelet sequestration site (PtSS) was determined on the basis of sequential patient and 
test-tube with 111In-oxinate imaging in anterior and posterior projection: at 20th minute, 2 
h, 4 h after labelled Pt intravenous injection and thereafter once a day untill circulating ra-
dioactivity falls to less than 20 % of the injected value. Regions of interest (ROI) were outli-
ned over the spleen, liver, heart and background radioactivity of the patient on anterior 
and posterior images, as well as over the test tube and its background. ROIs radioactivity 
values were corrected: a) for background, b) for gamma photons attenuation in the bed 
(on posterior projections only), c) for difference in the spleen and liver position (geometric 
mean of anterior and posterior projection radioactivity was calculated), d) for radioacti-
ve decay. PtSS was determined on the basis of platelet sequestration index (PtSI) value, 
calculated according to the formula: PtSI= (St/lt) / (S0/l0), where St is the radioactivity of 
the spleen at the time when more than 20% of circulating platelets disappeared from the 
circulation, Lt is the radioactivity of the liver at the same moment; S0 is the radioactivity of 
the spleen at the first image obtained at 20th minute after labelled Pt intravenous injection, 
l0 is the radioactivity of the liver at the same moment. In the case when initial labelled Pt 
kinetics was disturbed (during first 20 minutes after labelled Pt injection, on initial dyna-
mic study), instead of the first image at 20th minute, the second image at 2h was used as the 
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reference time point for PtSI calculation. For PtSI higher than 2,0 PtSS was the spleen (fig. 
2), for PtSI higher than 1,4 and lower or equal to 2, it was predominantly spleen, for PtSI 
values from 0,8-1,4 it was mixed, and for PtSI value lower than 0,8 it was the liver (fig. 3). 
2a. First image of the ITP patient (obtained at 20th minute after labelled platelets 
intravenous injection) in anterior position with outlined regions of interest over the 
spleen, liver, heart and background. Splenic and hepatic tissues are visualized. 
2b. Last image of the same patient. Only splenic tissue is visible.
 2a. 2b.
Figure 2. Labelled platelets sequestration in the spleen
 3a. 3b.
Figure 3. Labelled platelets sequestration in the liver
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3a. First image of the ITP patient in anterior position with outlined regions of 
interest. Splenic and hepatic tissues are visualized. 
3b. Last image of the same patient. Only hepatic tissue is visible. 
Platelet SS in controls was the liver (in 4 subjects, 66,7 %) and mixed (liver and spleen 
equally, in two persons, 33,3 %). There was no splenic nor predominantly splenic platelet 
sequestration in the control subjects. On the contrary, in ITP patients platelet SS was the 
spleen or predominantly spleen in 50,4 %, mixed in 34,4 % and hepatic in 15,2 %. 
Prediction of splenectomy results 
Up till now we have information about seventy eight splenectomized (splenic 
tissue operatively removed) ITP patients after performing labelled Pt investigation. 
In all patients (100 %) with PtSS in the spleen or predominantly in the spleen, sple-
nectomy results were good. In ITP patients with mixed Pt sequestration (in the sple-
en and in the liver equally), splenectomy results were good in 71 %. In ITP patients 
with hepatic Pt sequestration good splenectomy result was registered in only 20 %, 
while splenectomy failed in 80 %. Therefore, on the basis of labelled PtSS determi-
nation, it was possible to predict the efficacy of the splenectomy in our ITP patients. 
Splenectomy is advisable when PtSS is the spleen or predominantly spleen. On the 
contrary, in patients with hepatic Pt sequestration, splenectomy should be avoided. 
Our results are in agreement with the groups of Najean [13], Lamy (and Moisan) [14], 
Kinuya [15], Sarpatwari [16], Roca [17], while recent study of Navez [18] (in the group 
of 76 splenectomized ITP patients) claims that responce to splenectomy is indepen-
dent of the site of Pt sequestration. Cuker [19] is suspicious about the relationship 
between PtSS and splenectomy result and advices labelled PtSS investigation only 
in the centers with extensive experience with this modality. The reason for discre-
pancies in the literature is in the non-uniformity of the methodology for PtSS deter-
mination, and therefore standardized methods offering best results are needed [19]. 
CONCLUSION
On the basis of the results of labelled platelets lifespan, production and sequ-
estration site investigation, it was possible to confirm diagnosis of ITP in 477 (392 
adults and 85 children) out of 555 patients (86 %) with clinical diagnosis of ITP. In 
71 patient (69 adults and 2 children) out of 555 (13 %) ineffective platelet production 
was discovered as the mechanism of thrombocytopenia (patients had normal pla-
telet lifespan, and ITP was excluded), and there were 7 patients (1%) with pseudot-
hrombocytopenia (they had normal platelet lifespan, too). 
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This investigation enabled splenectomy result prediction in 65,6 % of ITP pati-
ents (with splenic and hepatic Pt sequestration site), visualization of 18 accessory 
spleens in 13 ITP patients (in 2,7 % of ITP patients)(6 in six patients investigated be-
fore splenectomy, and 12 in seven patients investigated after the splenectomy). Their 
role in thrombocytopenia could be estimated.
It was possible to detect unstable atherosclerotic plaques and acute thrombosis in 
ITP patients thanks to the images obtained after injection of labelled platelets. Focal 
zones of labelled platelets accumulation could be visualized at the places od unstable 
atherosclerotic plaques and acute thrombai. Chronic thrombosis could not be regi-
stered because of the finished thrombus formation and no more platelet deposition.
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Sažetak
Značaj autologno obilježenih trombocita indij-111 oksinatom  
u primarnoj imunološkoj trombocitopeniji u odraslih i djece
Metoda autolognog obilježavanja trombocita indij-111 oksinatom (111In-oxinate), određivanje 
vijeka, produkcije i mjesta sekvestracije obilježenih trombocita u Centru za nuklearnu medici-
nu Kliničkog centra Srbije je rezultat 24-godišnjeg osobnog iskustva u Beogradu, modifikacije i 
usavršavanja originalne metode. Opisana je usavršena metoda, kao i značenje ispitivanja vijeka 
trombocita, proizvodnje trombocita i mjesta njihove sekvestracije u 555 bolesnika starosti 3,1 
- 83 godine, sa kliničkom dijagnozom primarne imunološke trombocitopenije (ITP), kao i u 6 
kontrolnih zdravih osoba.
Na temelju dobivenih rezultata, potvrđena je dijagnoza ITP u 477 (392 odrasle osobe i 85 
djece) od 555 bolesnika (86 %) sa kliničkom dijagnozom ITP. U 71-og bolesnika (69 odraslih i 2 
djece) od 555 (13 %) otkrivena je nedostatna proizvodnja trombocita kao mehanizam tromboci-
topenije (pacijenti su imali normalan vijek trombocita, pa je dijagnoza ITP isključena), a bilo je i 
7 bolesnika (1%) sa pseudotrombocitopenijom (oni su također imali normalan vijek trombocita). 
Sedamdeset osam bolesnika sa ITP su splenektomirani nakon ispitivanja s obilježenim tromboci-
tima. Rezultati splenektomije su bili dobri u svih bolesnika (100%) sa slezenom ili predominan-
tno slezenom kao mjestom sekvestracije trombocita. U bolesnika s mješovitom sekvestracijom 
trombocita (u slezeni i jetri) rezultat splenektomije je bio dobar u 71 % operiranih bolesnika, a 
u bolesnika sa sekvestracijom trombocita u jetri u samo 20 %. Na osnovu određivanja mjesta 
sekvestracije obilježenih trombocita, bilo je moguće predvidjeti efikasnost splenektomije u bo-
lesnika s ITP.
Ovo ispitivanje je omogućilo vizualni prikaz 18 akcesornih slezena u 13 ITP bolesnika (2,7 % 
ITP pacijenata), kao i procjenu njihove uloge u trombocitopeniji. Vizualno su prikazani nestabilni 
aterosklerotični plakovi i akutne tromboze u bolesnika sa ITP. Nisu se mogli utvrditi stari trombi, 
zbog toga što je kod njih završen proces formiranja (nema više nakupljanja trombocita).
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